Day: December 9, 2024

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement Confirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatment Additional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatment Plans to continue monotherapy dose escalation and initiate combination studies in 1H 2025SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7...

Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments Treatment responses observed in heavily pre-treated population with mutations associated with poor prognosis and/or resistance to BTK inhibitors, including patients with CNS involvement Favorable safety profile across all doses tested Nurix will host a webcast to discuss the data presented at the ASH Annual Meeting and provide a corporate update today at 8:15 p.m. PT (11:15 p.m. ET) SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today presented new positive...

PRESS RELEASE Arcueil, December 9, 2024 Declaration of transactions on own shares conducted from December 2 to December 6, 2024 Within the framework of the authorizations granted by the General Assembly on February 9, 2024, to operate on its shares and in accordance with the regulations related to share buybacks, Aramis Group hereby declares the following purchases of own shares (FR0014003U94) made from December 2 to December 6, 2024 (excluding the liquidity contract):Name of the issuer Issuer identifier code Transaction date Financial instrument identifier code Total daily volume (in number of shares) Daily weighted average purchase price of shares MarketAramis Group 9695002Q984W0T41WB42 2024-12-02 FR0014003U94 14,869 7.4059 XPARAramis Group 9695002Q984W0T41WB42 2024-12-03 FR0014003U94...

ATLANTA, Dec. 09, 2024 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three month period ended October 31, 2024 on Monday December 16, 2024 after the close of the financial markets. The Company will conduct a conference call on Tuesday, December 17, 2024, at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291. A replay of the conference call will be available from Tuesday December 17, 2024, at 12:00 PM ET to Thursday December...

Basel, 9 December 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of November 25, 2024 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Blue Giant Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and Poseida. The tender offer period will expire at one minute following 11:59 p.m., New York City time on 7 January, 2025, unless the offer is extended. Roche has...

PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in high-performance optical networking solutions, proudly announces the general availability and production release of the industry’s first 100G ZR QSFP28 digital coherent optics (DCO) transceiver to operate over the Industrial temperature (I-temp) range from -40°C to +85°C. Leveraging the unparalleled efficiency of Steelerton™ digital signal processor (DSP) technology from Coherent, the I-temp 100G ZR QSFP28-DCO module sets a new standard for low power consumption, operating at an industry-leading 5.5W in a highly compact form factor. The innovative Steelerton™ DSP that powers the 100G ZR module is integrated with an innovative silicon photonics optical front-end and a power-optimized tunable laser, based on the Indium Phosphide...

CHIHUAHUA, Mexico, Dec. 09, 2024 (GLOBE NEWSWIRE) — GCC, S.A.B. de C.V. (BMV: GCC* or “the Company”), a leading producer of cement and concrete in the United States and Mexico, announces that Fitch Ratings has upgraded the Company’s local and foreign currency long-term Issuer Default Ratings (IDRs) and US$500 million senior notes due 2032 to ‘BBB’ from ‘BBB-‘, both with a stable outlook. The upgrade reflects GCC’s strong operating performance, solid organic growth and financial position. Fitch’s report highlights five key drivers behind GCC’s rating upgrade:Solid operating performance, supported by resilient demand and the Odessa plant expansion. Disciplined financial management, prioritizing a strong balance sheet and financial flexibility. Strategic expansion driven...